Skip to content
2000
Volume 26, Issue 7
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

Introduction

Secreted Frizzled-Related Protein 2 (SFRP2) is considered to be the most potent modulator of the Wnt signaling. This pathway is involved in the pathogenesis of Polycystic Ovary Syndrome (PCOS). This research aimed to compare the levels of SFRP2 in PCOS [infertile and Recurrent Pregnancy Loss (RPL) patients] with the control group and determine the correlation of SFRP2 with inflammation and insulin resistance.

Methods

This case-control study was conducted on 108 POCS patients (53 infertile patients and 55 women with RPL) and 54 healthy controls. The levels of biochemical factors along with SFRP2, adiponectin, Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), free testosterone, and insulin, high-sensitivity C-Reactive Protein (hs-CRP) were measured following the manufacturer's instructions.

Results

Both infertile and RPL groups presented notably higher levels of SFRP2 (49.32 ± 17.72 ng/ml and 55.89 ± 17.36 ng/ml, respectively) compared to the control group (30.21 ± 10.12 ng/ml, 0.001 for both groups). In PCOS patients, a positive correlation was observed between SFRP2 and body mass index (BMI) (r = 0.42, 0.001), insulin (r = 0.19, = 0.04), fasting blood glucose (FBG) (r = 0.24, = 0.01), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (r = 0.21, = 0.03), triglyceride (r = 0.25, = 0.009), and hs-CRP (r = 0.21, = 0.02). Furthermore, SFRP2 increased the risk of RPL (OR (95% CI) = 1.15 (1.10 -1.20), 0.001) and infertility (OR (95% CI) = 1.12 (1.07 -1.17), 0.001) in comparison with the controls.

Conclusion

Our findings suggested that SFRP2 may have a potential involvement in the development of PCOS and might be a promising target for diagnosis, but additional research is required to confirm this.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpps/10.2174/0113892037339007250120100322
2025-02-12
2025-09-04

  • From This Site

    /content/journals/cpps/10.2174/0113892037339007250120100322
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BicerM. AlarslanP. GulerA. DemirI. AslanipourB. CalanM. Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome.J. Endocrinol. Invest.202043330531310.1007/s40618‑019‑01108‑431486991
     [Google Scholar]
  2. JabeenA. YaminiV. Rahman AmberinaA. Dinesh EshwarM. VadakedathS. BegumG.S. KandiV. Polycystic ovarian syndrome: Prevalence, predisposing factors, and awareness among adolescent and young girls of South India.Cureus2022148e2794310.7759/cureus.2794336120281
     [Google Scholar]
  3. Escobar-MorrealeH.F. Luque-RamírezM. GonzálezF. Circulating inflammatory markers in polycystic ovary syndrome. A systematic review and metaanalysis.Fertil. Steril.20119531048105810.1016/j.fertnstert.2010.11.036
     [Google Scholar]
  4. İnalH.A. YilmazN. GorkemU. OrucA.S. TimurH. The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS.J. Endocrinol. Invest.201639443143710.1007/s40618‑015‑0392‑626410834
     [Google Scholar]
  5. BarberT. FranksS. Genetic and Environmental Factors in the Etiology of Polycystic Ovary Syndrome. The Ovary.Elsevier201943745910.1016/B978‑0‑12‑813209‑8.00027‑3
     [Google Scholar]
  6. XuY. QiaoJ. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): A review of literature.J. Healthc. Eng.20222022111310.1155/2022/924056935356614
     [Google Scholar]
  7. VatannejadA. FadaeiR. SalimiF. FouaniF.Z. HabibiB. ShapourizadehS. EivaziS. EivaziS. SadeghiA. MoradiN. Plasma Complement C1q/tumor necrosis factor-related protein 15 concentration is associated with polycystic ovary syndrome.PLoS One2022176e026365810.1371/journal.pone.026365835700181
     [Google Scholar]
  8. KamalanathanS. SahooJ. SathyapalanT. Pregnancy in polycystic ovary syndrome.Indian J. Endocrinol. Metab.2013171374310.4103/2230‑8210.10783023776851
     [Google Scholar]
  9. WartenaR. MatjilaM. Polycystic ovary syndrome and recurrent pregnancy loss, a review of literature.Front. Endocrinol.202314118306010.3389/fendo.2023.118306038027110
     [Google Scholar]
  10. CenaH. ChiovatoL. NappiR.E. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists.J. Clin. Endocrinol. Metab.20201058e2695e270910.1210/clinem/dgaa28532442310
     [Google Scholar]
  11. DimitriadisG. KyrouI. RandevaH. Polycystic ovary syndrome as a proinflammatory state: The role of adipokines.Curr. Pharm. Des.201622365535554610.2174/138161282266616072610313327464726
     [Google Scholar]
  12. InalZ.O. InalH.A. ErdemS. The effect of serum and follicular fluid secreted frizzle-related protein-5 on in vitro fertilization outcomes in patients with polycystic ovary syndrome.Mol. Biol. Rep.20184562037204410.1007/s11033‑018‑4360‑z30194556
     [Google Scholar]
  13. WangY. ZhuW. Evaluation of adiponectin, resistin, IL-6, TNF-α in obese and non-obese women with polycystic ovary syndrome.Reprod. Contracept.201223423724410.1016/S1001‑7844(12)60032‑7
     [Google Scholar]
  14. MamanE. YungY. CohenB. KonopnickiS. Dal CantoM. FadiniR. KanetyH. KedemA. DorJ. HourvitzA. Expression and regulation of sFRP family members in human granulosa cells.Mol. Hum. Reprod.201117739940410.1093/molehr/gar01021307090
     [Google Scholar]
  15. AlhilfiA.S.N. AfrishamR. SefidanA.M. FadaeiR. MoradiN. SaedL. EinollahiN. A positive correlation of serum SFRP1 levels with the risk of developing type 2 diabetes mellitus: A case- control study.Lab. Med.202455673974410.1093/labmed/lmae03038801722
     [Google Scholar]
  16. ZhangY. RanY. KongL. GengL. HuangH. ZhangH. HuJ. QiH. ChenY. Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: Implication of its role in dysregulated metabolism.J. Ovarian Res.20211419710.1186/s13048‑021‑00847‑434284806
     [Google Scholar]
  17. CrowleyR.K. O’ReillyM.W. BujalskaI.J. Hassan-SmithZ.K. HazlehurstJ.M. FoucaultD.R. StewartP.M. TomlinsonJ.W. SFRP2 is associated with increased adiposity and VEGF expression.PLoS One2016119e016377710.1371/journal.pone.016377727685706
     [Google Scholar]
  18. AjmalN. KhanS.Z. ShaikhR. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article.Eur. J. Obstet. Gynecol. Reprod. Biol.2019310006010.1016/j.eurox.2019.10006031403134
     [Google Scholar]
  19. CaoM. WangH. LiW. JiangX. WangX. GuoW. GaoP. ZouY. Inverse associations between circulating secreted frizzled related protein 2 (sFRP2) and cardiometabolic risk factors.Front. Cardiovasc. Med.2021872320510.3389/fcvm.2021.72320534722660
     [Google Scholar]
  20. Kumar ShrewastwaM. AcharyaV. Kumar MahatA. Association of secreted frizzled-related protein 4 with obesity and type II diabetes.Nepal Med. J.202352505610.37080/nmj.148
     [Google Scholar]
  21. BeerninkR.H. SchuitemakerJ.H. Secreted Frizzled-Related Proteins 4 and 5: What They Are and Can They Be Used as a Biomarker in Gestational Diabetes Mellitus. Biomarkers in Diabetes.Springer2022629648
     [Google Scholar]
  22. ZhouM. JiaoL. LiuY. sFRP2 promotes airway inflammation and Th17/Treg imbalance in COPD via Wnt/β-catenin pathway.Respir. Physiol. Neurobiol.201927010328210.1016/j.resp.2019.10328231430541
     [Google Scholar]
  23. BujalskaI. RabbittE. StewartP. Effect of secreted frizzled-related protein 2 (sFRP2) from adipose tissue on pancreatic cell function. Endocrine Abstracts.Bioscientifica2012
     [Google Scholar]
  24. CercatoC. FonsecaF.A. Cardiovascular risk and obesity.Diabetol. Metab. Syndr.20191117410.1186/s13098‑019‑0468‑031467596
     [Google Scholar]
  25. EhrlundA. MejhertN. Lorente-CebriánS. AströmG. DahlmanI. LaurencikieneJ. RydénM. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue.J. Clin. Endocrinol. Metab.2013983E503E50810.1210/jc.2012‑341623393180
     [Google Scholar]
  26. MastriM. ShahZ. HsiehK. WangX. WooldridgeB. MartinS. SuzukiG. LeeT. Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention.Am. J. Physiol. Cell Physiol.20143066C531C53910.1152/ajpcell.00238.201324336656
     [Google Scholar]
/content/journals/cpps/10.2174/0113892037339007250120100322
Loading
Circulating SFRP2 in Iranian Polycystic Ovarian Syndrome Patients with Infertility and Recurrent Pregnancy Loss and its Correlation with Insulin Resistance and Inflammation
Curr. Protein Pept. Sci. 26, 585 (2025); https://doi.org/10.2174/0113892037339007250120100322
/content/journals/cpps/10.2174/0113892037339007250120100322
/content/journals/cpps/10.2174/0113892037339007250120100322
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): infertility; inflammation; insulin resistance; polycystic ovary syndrome; recurrent pregnancy loss; Secreted frizzled-related protein 2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test